<\/p>\n
As the World Health Organization recently issued guidance supporting the use of GLP-1 medications in obesity care, these drugs reached a new milestone. For patients, it marks a much-needed shift away from willpower-based narratives and toward understanding weight as something rooted in biology.<\/p>\n
But long before Ozempic and Wegovy became household names, the story of GLP-1s started with early gut-hormone research\u2014and an unlikely breakthrough courtesy of a venomous desert lizard. Below, experts walk us through the science of GLP-1s: where it began, what we\u2019ve learned and where the field is headed next.<\/p>\n
In the 1980s and 1990s, researchers were trying to understand how the body regulates blood sugar after meals. That work led to the discovery of glucagon-like peptide-1 (GLP-1), a hormone released from the small intestine that helps control insulin secretion, slow digestion and reduce appetite. \u201cEarly researchers noticed that GLP-1 powerfully and appropriately stimulated insulin only when glucose levels were high, meaning it lowered blood sugar without causing dangerous hypoglycemia,\u201d says New York internist and longevity expert Amanda Kahn, MD. \u201cIt also slowed gastric emptying and reduced appetite, which immediately made it different from other diabetes hormones.\u201d<\/p>\n
The problem was timing: natural GLP-1 is broken down within minutes, making it impractical as a medication. For a while, it seemed like promising biology without a path forward.<\/p>\n
Then the answer arrived from an unexpected place: the Gila monster, a venomous desert lizard known for eating infrequently and surviving long periods without food. \u201cThe saliva of the Gila monster creates a substance that looks very similar to the GLP-1 our body naturally makes,\u201d explains Andrea Traina,\u00a0PharmD,\u00a0obesity\u00a0medical\u00a0director for Novo Nordisk. \u201cWhat the Gila monster makes is Exendin 4. This became the basis for exenatide, the first GLP-1\u00a0receptor agonist medication\u00a0approved in 2005. It was short-acting, lasted a few\u00a0hours and\u00a0was\u00a0dosed twice a day\u00a0before meals. That little lizard completely revolutionized our understanding of appetite control,\u00a0and\u00a0glucose metabolism,\u201d says Traina. \u201cThe scientific community\u00a0has\u00a0learned so much from it.\u201d<\/p>\n
What made Exendin 4 different was durability. It resisted rapid breakdown, giving scientists a blueprint for designing longer-acting drugs. \u201cThat little lizard completely revolutionized our understanding of appetite control, glucose metabolism and inflammation,\u201d says Traina. \u201cWe have learned so much from it.\u201d<\/p>\n
When exenatide reached diabetes clinics, doctors noticed something unexpected. Patients not only improved their blood sugar levels but also lost meaningful weight. \u201cClinicians began noticing significant weight loss in diabetes patients taking early GLP-1 drugs like exenatide and liraglutide in the mid-2000s,\u201d says Dr. Kahn. \u201cThe turning point came around 2015, when higher-dose liraglutide, under the brand name Saxenda, was approved for obesity, confirming the weight loss effect wasn\u2019t just a side effect, but a primary therapeutic action.\u201d<\/p>\n
GLP-1s worked differently from earlier diet drugs. \u201cThe reason many people struggle to lose weight with lifestyle changes alone is that the biology gets in the way,\u201d says San Diego internist and obesity specialist Eduardo Grunvald, MD. \u201cThese medications reduce hunger, cravings and the reward response to high-fat, high-sugar foods, helping people feel full with less food.\u201d For many patients, that shift shows up as quiet. Fewer cravings. Less food noise.<\/p>\n
Semaglutide, the active ingredient in Wegovy and Ozempic, pushed the class further. Large trials showed benefits that extended beyond weight alone. \u201cWe have a medication that is well known, respected and proven safe and effective beyond the scale,\u201d notes Traina. \u201cNot just weight reduction, but reductions in heart attack, stroke and cardiovascular death.\u201d Those findings helped reposition GLP-1s as long-term metabolic therapies rather than short-term fixes.<\/p>\n
The next phase of the GLP-1 story is less about format and more about stability in the body over time, a shift that became tangible in December 2025 when the FDA approved Novo Nordisk\u2019s oral semaglutide (Wegovy), the first daily GLP-1 pill cleared for obesity treatment. What was once investigational is now reality. As scientists learned how to make these medications last longer in our systems, the focus shifted to whether that same consistency could extend beyond injections. \u201cWe now have a medication that\u2019s proven for safety and efficacy beyond the scale available in a daily pill with a similar safety and efficacy profile to the once-weekly injection,\u201d says Traina. \u201cThat\u2019s really first of its kind.\u201d<\/p>\n
Getting there took decades. \u201cGLP-1s are peptide-based molecules that aren\u2019t designed to be absorbed orally,\u201d Traina explains. \u201cIt took years of research to develop a formulation that temporarily changes the stomach environment, protects the drug from being broken down and allows enough semaglutide to be absorbed to have a therapeutic effect.\u201d<\/p>\n
In late-stage trials, patients taking the highest oral dose of Wegovy lost about 14 percent of their body weight, results comparable to the injectable version. Like its once-weekly counterpart, the pill is also approved to reduce cardiovascular risk, reinforcing the idea that GLP-1 medications are now viewed as long-term metabolic therapies rather than short-term weight-loss tools.<\/p>\n
The tablet must be taken on an empty stomach, with a 30-minute window before eating, reflecting the precision required to allow absorption in the digestive tract. Still, the approval marks a meaningful expansion in access. Weekly injections remain foundational, but daily oral therapy adds another entry point into care, particularly for patients hesitant about needles or seeking a treatment that fits more seamlessly into a morning routine.<\/p>\n
While the story begins with a lizard, its impact reaches much further. \u201cGLP-1 showed us that the gut has been acting like an endocrine organ all along,\u201d says Dr. Kahn. \u201cBy paying attention to it, we uncovered one of the most powerful tools for metabolic health and longevity that medicine has identified.\u201d<\/p>\n
For many people on GLP-1s, the experience has been quietly validating\u2014confirming that what they were missing wasn\u2019t willpower but the biological switch that silences food noise, a discovery that traces all the way back to the Gila monster.<\/p>\n<\/p><\/div>\n